ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors

Gainor, 2016, Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer, Cancer Discov, 6, 1118, 10.1158/2159-8290.CD-16-0596 Xia, 2020, Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR. NSCLC: results from a large-scale survey of NTRK1 fusions in chinese patients with lung cancer, Clin. Lung Cancer, 21, 247, 10.1016/j.cllc.2019.09.004 Camidge, 2019, Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib in untreated ALK-Positive advanced non-small cell lung cancer in the global phase III ALEX study, J. Thorac. Oncol., 14, 1233, 10.1016/j.jtho.2019.03.007 Kang, 2020, Complex ALK fusions are associated with better prognosis in advanced non- small cell lung cancer, Front. Oncol., 10, 10.3389/fonc.2020.596937 Zugazagoitia, 2019, Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor, Lung Cancer, 134, 72, 10.1016/j.lungcan.2019.05.032 Kummar, 2018, TRK inhibition: a new tumor-agnostic treatment strategy, Target Oncol., 13, 545, 10.1007/s11523-018-0590-1 Farago, 2018, Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion, JCO Precis Oncol., 10.1200/PO.18.00037 Jin, 2020, Roles of TrkC signaling in the regulation of tumorigenicity and metastasis of cancer, Cancers, 12, 147, 10.3390/cancers12010147 Baldi, 2014, Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells, Lung Cancer, 86, 291, 10.1016/j.lungcan.2014.09.011 Drilon, 2017, Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1), Cancer Discov., 7, 400, 10.1158/2159-8290.CD-16-1237